• Thursday, Oct 01, 2020
  • Last Update : 10:52 pm

Indonesia eyes production of 250m doses a year of coronavirus vaccine

  • Published at 07:54 pm August 4th, 2020
Indonesia: The Bio Farma office in Covid-19 vaccine production
Staff are seen in the Covid-19 vaccine production facility area at the Bio Farma office amid the coronavirus pandemic in Bandung, West Java province, Indonesia August 4, 2020 Reuters

State-run pharmaceutical firm Bio Farma will begin phase three of clinical trials in humans this week using a vaccine produced by China's Sinovac

Indonesia will have capacity to produce 250 million doses a year of a coronavirus vaccine by the end of 2020 pending trials on humans, a minister said on Tuesday, as the country seeks to halt a wave of infections that has shown no sign of relent.

Indonesia has confirmed 115,056 cases of Covid-19 and 5,388 deaths since its first infections in March. It has been reporting more than 1,000 new cases on most days since the start of June.

State-run pharmaceutical firm Bio Farma will begin phase three of clinical trials in humans this week using a vaccine produced by China's Sinovac. If those are successful, Bio Farma has said would produce the vaccine itself.

The global pandemic has sparked a scramble to create a vaccine, with more than 100 in development and about a dozen already being tested on humans. There are concerns, however, about demand and developing countries' access to a future jab.

Erick Thohir, Indonesia's minister for state-owned enterprises, said Bio Farma would raise capacity in the coming months and by year-end would be ready to produce 250 million doses a year.

"Let's trust the capability of our country. Don't doubt Bio Farma which has been proven, either to produce vaccines that are produced with international partners or vaccines produced solely by (them)," Thohir said in a statement.

The Indonesian trials will be conducted in West Java involving about 1,600 volunteers, according to the website of the West Java government.

Sinovac did not immediately respond to a request for comment. It is also working with Bangladesh and Brazil for the clinical trials.

Bambang Heriyanto, corporate secretary at Bio Farma, told Reuters the targeted production capacity to 250 million doses was contingent on the vaccine passing the trial.

73
60
blogger sharing button blogger
buffer sharing button buffer
diaspora sharing button diaspora
digg sharing button digg
douban sharing button douban
email sharing button email
evernote sharing button evernote
flipboard sharing button flipboard
pocket sharing button getpocket
github sharing button github
gmail sharing button gmail
googlebookmarks sharing button googlebookmarks
hackernews sharing button hackernews
instapaper sharing button instapaper
line sharing button line
linkedin sharing button linkedin
livejournal sharing button livejournal
mailru sharing button mailru
medium sharing button medium
meneame sharing button meneame
messenger sharing button messenger
odnoklassniki sharing button odnoklassniki
pinterest sharing button pinterest
print sharing button print
qzone sharing button qzone
reddit sharing button reddit
refind sharing button refind
renren sharing button renren
skype sharing button skype
snapchat sharing button snapchat
surfingbird sharing button surfingbird
telegram sharing button telegram
tumblr sharing button tumblr
twitter sharing button twitter
vk sharing button vk
wechat sharing button wechat
weibo sharing button weibo
whatsapp sharing button whatsapp
wordpress sharing button wordpress
xing sharing button xing
yahoomail sharing button yahoomail